ZYME Zymeworks Inc

Price (delayed)

$6.3

Market cap

$363.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.42

Enterprise value

$120.16M

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of ...

Highlights
The quick ratio has declined by 36% year-on-year but it has increased by 2.1% since the previous quarter
The company's equity fell by 25% YoY but it rose by 13% QoQ
Zymeworks's net income has decreased by 24% YoY and by 13% QoQ
ZYME's EPS is down by 16% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of ZYME
Market
Shares outstanding
57.77M
Market cap
$363.96M
Enterprise value
$120.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
13.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.3
Earnings
Revenue
$27.95M
EBIT
-$240.99M
EBITDA
-$228.7M
Free cash flow
-$222.93M
Per share
EPS
-$4.42
Free cash flow per share
-$3.63
Book value per share
$4.89
Revenue per share
$0.46
TBVPS
$6.73
Balance sheet
Total assets
$429.98M
Total liabilities
$147.53M
Debt
$31.72M
Equity
$282.44M
Working capital
$244.05M
Liquidity
Debt to equity
0.11
Current ratio
4.05
Quick ratio
3.81
Net debt/EBITDA
1.07
Margins
EBITDA margin
-818.2%
Gross margin
100%
Net margin
-858.2%
Operating margin
-870.7%
Efficiency
Return on assets
-56.1%
Return on equity
-84.8%
Return on invested capital
-202.3%
Return on capital employed
-68.9%
Return on sales
-862.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZYME stock price

How has the Zymeworks stock price performed over time
Intraday
-0.32%
1 week
3.28%
1 month
8.43%
1 year
-82.83%
YTD
-61.56%
QTD
-3.82%

Financial performance

How have Zymeworks's revenue and profit performed over time
Revenue
$27.95M
Gross profit
$27.95M
Operating income
-$243.38M
Net income
-$239.88M
Gross margin
100%
Net margin
-858.2%
The company's net margin fell by 39% YoY and by 8% QoQ
The operating margin has decreased by 39% YoY and by 8% from the previous quarter
Zymeworks's net income has decreased by 24% YoY and by 13% QoQ
ZYME's operating income is down by 24% year-on-year and by 13% since the previous quarter

Growth

What is Zymeworks's growth rate over time

Valuation

What is Zymeworks stock price valuation
P/E
N/A
P/B
1.29
P/S
13.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.3
ZYME's EPS is down by 16% year-on-year and by 8% since the previous quarter
ZYME's P/B is 64% below its last 4 quarters average of 3.6 and 63% below its 5-year quarterly average of 3.5
The company's equity fell by 25% YoY but it rose by 13% QoQ
The stock's price to sales (P/S) is 72% less than its last 4 quarters average of 49.7 and 62% less than its 5-year quarterly average of 36.8
Zymeworks's revenue has decreased by 11% YoY but it has increased by 4.8% from the previous quarter

Efficiency

How efficient is Zymeworks business performance
ZYME's ROIC has dropped by 124% year-on-year and by 24% since the previous quarter
Zymeworks's return on equity has shrunk by 87% YoY and by 23% QoQ
Zymeworks's ROA has plunged by 59% YoY and by 17% from the previous quarter
ZYME's ROS is down by 40% year-on-year and by 8% since the previous quarter

Dividends

What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZYME.

Financial health

How did Zymeworks financials performed over time
Zymeworks's total assets is 191% higher than its total liabilities
The quick ratio has declined by 36% year-on-year but it has increased by 2.1% since the previous quarter
The company's current ratio fell by 34% YoY
The company's debt is 89% lower than its equity
The company's equity fell by 25% YoY but it rose by 13% QoQ
The debt to equity is down by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.